Lantheus Holdings (LNTH)

$70.57 -0.62 (-0.87%)
Market Cap 4.88B
Revenue (ttm) 1.53B
Net Income (ttm) 312.44M
EPS (ttm) N/A
PE Ratio 12.42
Forward PE 12.45
Profit Margin 20.37%
Debt to Equity Ratio 0.49
Volume 943,100
Avg Vol 1,025,922
Day's Range N/A - N/A
Shares Out 69.19M
Stochastic %K 27%
Beta 0.14
Analysts Strong Sell
Price Target $128.92

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 978 671 8001
Fax: 978 671 8860
Address:
201 Burlington Road, South Building, Bedford, United States
Ilya136
Ilya136 Aug. 3 at 3:12 PM
The only thing I’m concerned about when it comes to $LNTH are bad reviews by employees at some lower ranking positions, but it seems like workers in the R&D department and product management are more satisfied which is nice.
0 · Reply
RADX_enjoyer
RADX_enjoyer Aug. 3 at 12:51 AM
$RADX Lots of top instos, insiders, and US health funds are holding this, 80% owned by the top 20 holders list. The numbers are a little outdated, but $LNTH owns an additional 133m shares. These numbers are for the Australian listing, so just divide the shares by 300 to get the equivalent holding on the Nasdaq.
0 · Reply
DKFutureInvest
DKFutureInvest Aug. 1 at 3:06 AM
$LNTH The 1500 puts at $80 for the 15th has me a bit concerned. I wonder if we’re developing another bear flag and will drop on earnings even with a nice beat. Thoughts?
1 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 30 at 11:04 AM
$RADX Tiny float, $35M market cap, 12% of the company owned by Lantheus (biggest company specialising in radiopharmaceuticals). Price target $18/share, analyst coverage by 6 different US brokers, with 3 data readouts within the next few months (one Phase 2b, two x Phase 1 trials). I'm trusting $LNTH know what they're investing in
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 29 at 12:20 PM
FDA fast track designation for our leading product, all trials are on schedule, cashed up for the next 1 year until mid 2026, $LNTH Lantheus owns 12%, what is not to love about $RADX 🚀🚀
0 · Reply
sc0re2day
sc0re2day Jul. 29 at 11:32 AM
$LNTH AstraZeneca beat handily and maintained, Merck missed by a hair, trimmed guidance, and needs to restructure for cost savings. Earnings never easy to predict, but I'm riding this one out. We'll see. Obviously $5 billion company not in same league as those two.
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 28 at 1:40 PM
The largest radiopharm company $LNTH just can't get enough of $RADX . Lantheus owns 12% of RADX at a huge premium of $12/share, the stock is currently trading at $4.80. Absolutely underrated IMO
1 · Reply
RadioIsotope25
RadioIsotope25 Jul. 25 at 6:41 PM
Australian radiopharmaceutical market is hot Clarity Pharmaceuticals market cap just tripled to $920 million and Telix Market cap is $4.7 billion. Makes Radiopharma Theranostics looks very cheap at $35 million market cap. Imaging data out soon could be next big winner. $RADX $MNPR $LNTH $IOVA
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 24 at 10:11 PM
$LNTH added to this and $CPRX today
0 · Reply
sc0re2day
sc0re2day Jul. 23 at 11:26 PM
$LNTH They're putting in the work. Now let's see some positive results:
0 · Reply
Latest News on LNTH
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

Jul 22, 2025, 7:00 AM EDT - 12 days ago

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

Lantheus Holdings: Forget The Short Term Noise

Jul 21, 2025, 8:57 AM EDT - 13 days ago

Lantheus Holdings: Forget The Short Term Noise

Why Is Lantheus Stock Trading Lower On Wednesday?

Jul 16, 2025, 2:45 PM EDT - 18 days ago

Why Is Lantheus Stock Trading Lower On Wednesday?

Lantheus Seems Worth The (Very Real) Risks

Jul 1, 2025, 7:28 AM EDT - 4 weeks ago

Lantheus Seems Worth The (Very Real) Risks

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Jun 11, 2025, 4:01 PM EDT - 7 weeks ago

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Jun 10, 2025, 8:30 AM EDT - 7 weeks ago

Lantheus to Present at the 2025 Truist Securities MedTech Conference

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

Jun 2, 2025, 8:00 AM EDT - 2 months ago

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

GEHC

Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy

May 14, 2025, 3:26 PM EDT - 2 months ago

Lantheus Holdings: Poor Results Caused By Temporary Problems - A Buy

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

May 8, 2025, 6:50 PM EDT - 3 months ago

Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH

Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:23 AM EDT - 3 months ago

Lantheus Holdings, Inc. (LNTH) Q1 2025 Earnings Call Transcript

Lantheus Announces Sale of SPECT Business to SHINE Technologies

May 6, 2025, 4:01 PM EDT - 3 months ago

Lantheus Announces Sale of SPECT Business to SHINE Technologies

Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Apr 30, 2025, 8:30 AM EDT - 3 months ago

Lantheus Announces Alzheimer's Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

Apr 23, 2025, 8:30 AM EDT - 3 months ago

Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time

Lantheus Completes Acquisition of Evergreen Theragnostics

Apr 1, 2025, 9:00 AM EDT - 4 months ago

Lantheus Completes Acquisition of Evergreen Theragnostics

Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry

Mar 7, 2025, 11:12 AM EST - 5 months ago

Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry

Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 10:49 AM EST - 5 months ago

Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.

Jan 30, 2025, 8:30 AM EST - 6 months ago

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D.

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Jan 28, 2025, 6:30 AM EST - 6 months ago

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Jan 13, 2025, 12:05 AM EST - 7 months ago

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Lantheus Holdings: Powerhouse Potential In 2025

Jan 1, 2025, 7:43 PM EST - 7 months ago

Lantheus Holdings: Powerhouse Potential In 2025

Lantheus Holdings: A Growing Business With Dominant Market Share

Dec 12, 2024, 2:01 PM EST - 8 months ago

Lantheus Holdings: A Growing Business With Dominant Market Share

Lantheus Announces Share Repurchase Program

Nov 20, 2024, 1:00 AM EST - 9 months ago

Lantheus Announces Share Repurchase Program

Lantheus to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 9 months ago

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Nov 11, 2024, 7:39 AM EST - 9 months ago

Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Nov 8, 2024, 10:06 AM EST - 9 months ago

Lantheus Holdings: Q3 Results Were Good But Market Overreacted

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 11:27 AM EST - 9 months ago

Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Nov 4, 2024, 7:30 AM EST - 9 months ago

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Oct 23, 2024, 8:30 AM EDT - 10 months ago

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Sep 15, 2024, 8:45 AM EDT - 11 months ago

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus Appoints Julie Eastland as New Board Member

Sep 5, 2024, 8:30 AM EDT - 11 months ago

Lantheus Appoints Julie Eastland as New Board Member

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

Aug 12, 2024, 3:32 PM EDT - 1 year ago

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

13 stocks to consider if you're able to brave recession fears

Aug 12, 2024, 7:15 AM EDT - 1 year ago

13 stocks to consider if you're able to brave recession fears

CWAN ESNT FUL ISRG KO MA MKTX

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:18 PM EDT - 1 year ago

Lantheus Holdings, Inc. (LNTH) Q2 2024 Earnings Call Transcript

Lantheus Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Lantheus Reports Second Quarter 2024 Financial Results

10 Stocks That Star Small-Cap Funds Love

Jul 29, 2024, 2:00 AM EDT - 1 year ago

10 Stocks That Star Small-Cap Funds Love

ATKR AZEK FIX FN HQY MOD MTDR

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Jul 15, 2024, 8:30 AM EDT - 1 year ago

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)

Jul 12, 2024, 11:40 AM EDT - 1 year ago

Lantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Jul 10, 2024, 12:32 PM EDT - 1 year ago

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Ilya136
Ilya136 Aug. 3 at 3:12 PM
The only thing I’m concerned about when it comes to $LNTH are bad reviews by employees at some lower ranking positions, but it seems like workers in the R&D department and product management are more satisfied which is nice.
0 · Reply
RADX_enjoyer
RADX_enjoyer Aug. 3 at 12:51 AM
$RADX Lots of top instos, insiders, and US health funds are holding this, 80% owned by the top 20 holders list. The numbers are a little outdated, but $LNTH owns an additional 133m shares. These numbers are for the Australian listing, so just divide the shares by 300 to get the equivalent holding on the Nasdaq.
0 · Reply
DKFutureInvest
DKFutureInvest Aug. 1 at 3:06 AM
$LNTH The 1500 puts at $80 for the 15th has me a bit concerned. I wonder if we’re developing another bear flag and will drop on earnings even with a nice beat. Thoughts?
1 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 30 at 11:04 AM
$RADX Tiny float, $35M market cap, 12% of the company owned by Lantheus (biggest company specialising in radiopharmaceuticals). Price target $18/share, analyst coverage by 6 different US brokers, with 3 data readouts within the next few months (one Phase 2b, two x Phase 1 trials). I'm trusting $LNTH know what they're investing in
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 29 at 12:20 PM
FDA fast track designation for our leading product, all trials are on schedule, cashed up for the next 1 year until mid 2026, $LNTH Lantheus owns 12%, what is not to love about $RADX 🚀🚀
0 · Reply
sc0re2day
sc0re2day Jul. 29 at 11:32 AM
$LNTH AstraZeneca beat handily and maintained, Merck missed by a hair, trimmed guidance, and needs to restructure for cost savings. Earnings never easy to predict, but I'm riding this one out. We'll see. Obviously $5 billion company not in same league as those two.
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 28 at 1:40 PM
The largest radiopharm company $LNTH just can't get enough of $RADX . Lantheus owns 12% of RADX at a huge premium of $12/share, the stock is currently trading at $4.80. Absolutely underrated IMO
1 · Reply
RadioIsotope25
RadioIsotope25 Jul. 25 at 6:41 PM
Australian radiopharmaceutical market is hot Clarity Pharmaceuticals market cap just tripled to $920 million and Telix Market cap is $4.7 billion. Makes Radiopharma Theranostics looks very cheap at $35 million market cap. Imaging data out soon could be next big winner. $RADX $MNPR $LNTH $IOVA
0 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 24 at 10:11 PM
$LNTH added to this and $CPRX today
0 · Reply
sc0re2day
sc0re2day Jul. 23 at 11:26 PM
$LNTH They're putting in the work. Now let's see some positive results:
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 23 at 11:07 AM
$LNTH have finally completed the acquisition of Life Molecular Imaging. With Lantheus currently owning 12.12% of $RADX , will Radiopharm Theranostics be next on the M&A radar? Lantheus' CEO Brian Markison has previously stated how much he likes the company.
0 · Reply
RADX_enjoyer
RADX_enjoyer Jul. 23 at 5:54 AM
Brookline Capital are extremely happy about $LNTH 's 12% stock ownership in $RADX . Price target set to US$18, which is a massive 300% premium to today's closing price of only US4.50. Analyst report is available on the company website: https://radiopharmtheranostics.com/radiopharm-theranostics-nasdaq-radx-initiate-with-a-buy-rating-and-18-target-price/
2 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 22 at 11:23 PM
$LNTH $CPRX $IAC So many amazing slow growing value stocks out there (like these!) but FOMO retail loves chasing money-losing bankruptcy plays pumped by WSBs.
1 · Reply
Nosh
Nosh Jul. 21 at 9:19 PM
$LNTH Wow this one just became very interesting.
0 · Reply
HappE
HappE Jul. 21 at 8:15 AM
$LNTH 8-9mil short plus those Puts in effect...short-termers beware and those stop-losses get gobbled. Speaking of gobbled, I can't help but eat these 70s. Almost to 5k shares.
2 · Reply
RadioIsotope25
RadioIsotope25 Jul. 20 at 2:45 PM
Her2 Lu-177 is showing 30-40% responses in other similar trials. Should provide great upside to RADX 3q data $RADX $LNTH $MNPR
1 · Reply
Chomo
Chomo Jul. 19 at 12:43 AM
$LNTH semana desastrosa.
1 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 18 at 8:16 PM
$LNTH how can you lose money with this stock? Whenever it dumps into the $70S it always has a massive rebound. Only “get rich quick” FOMO buyers will lose here!
1 · Reply
TPTradingCo
TPTradingCo Jul. 17 at 9:58 PM
$LNTH $90 before $70. Booyah, Jim…
1 · Reply
HappE
HappE Jul. 17 at 6:28 PM
$LNTH The level of manipulation on this one is reaching epic levels. Someone bought about 2k puts after those 4k puts printed. So not surpised. 2026 is where the rubber meets the road. Could be ahwile still.
1 · Reply
ChromeOnTheWheels
ChromeOnTheWheels Jul. 16 at 9:26 PM
$CPRX this and $LNTH are long term winners. Day traders won’t make any money here, but longs will.
0 · Reply
MikeyNJ
MikeyNJ Jul. 16 at 5:39 PM
$LNTH Have never been able to get a grasp on fundamentals here. However, these quick selloffs seem to be a common occurrence and the stock always recovers. I have taken the opportunity to use them as a trade and this time is no different. Just bought down here and will kick them out on the recovery.
0 · Reply